Foot-And-Mouth Disease

FREDERICK, Md., March 11, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces a new groundbreaking study demonstrating the effectiveness of its solutions against foot-and-mouth disease virus (FMDV). This significant advancement supports the Company’s submission for an additional EPA label. Foot-and-mouth disease (FMD) represents a critical global threat, being an extremely contagious disease affecting a wide range of cloven-hoofed animals including cows, pigs, sheep, goats, and deer. The rapid spread of FMDV among livestock can lead to significant economic losses and disrupt international trade if not promptly and effectively controlled. TOMI’s recent study has proven SteraMist iHP technology to eliminate infectious FMDV from both porous (concrete) and non-porous (stainless steel) surfaces in the presence of organic soil load. This achievement meets the stringent EPA standards for demonstrating virucidal efficacy. The study, conducted by the Department of Homeland Security (DHS) Science and Technology Directorate’s (S&T’s) Plum Island Animal Disease Center (PIADC), adhered to the strict regulatory guidelines of the U.S. Select Agent Program and utilized methods aligned with EPA-approved testing standards. Dr. Halden Shane, CEO of TOMI, emphasizes the critical nature of combating Transboundary Animal Disease (TAD) outbreaks, such as FMD, “These diseases not only disrupt domestic agricultural production but may also severely impact international trade of agricultural commodities. TADs have the potential to cause widespread economic and societal damage, particularly in regions where agricultural animals are a primary livelihood. Our mission extends into the food safety sector, aiming to halt the transmission of viruses and prevent cross-contamination. This latest study underscores our commitment to providing effective solutions in the fight against global animal diseases," Dr. Halden Shane remarked. TOMI continues conducting research to strengthen its role as a crucial advocate for advancing global health and ensuring food safety, protecting against infectious diseases. TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments. For additional information, please visit http://www.steramist.com/ or contact us at info@tomimist.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to the ability of TOMI’s products to eliminate infectious diseases. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended March 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.com

XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- It was recently announced that Tianlong Technology complies with the requirements of Chinese Good Manufacturing Practices for animal drugs. This approval further ensures Tianlong's focus on standardized workflows in the development of animal products. Continue Reading Tianlong Solution for Livestock Disease Detection Over the last 26 years, Tianlong Technology has been committed to delivering all-encompassing solutions for molecular diagnostics and genetic testing. In the field of livestock husbandry, Tianlong provides pioneering disease detection solutions, comprising a variety of instruments and matching reagents that allow for swift and reliable detection of swine fever, African swine fever, porcine reproductive and respiratory syndrome, porcine viral diarrhea, foot-and-mouth disease, and avian influenza, among others. Tianlong's livestock disease detection solution comprises a range of instruments including GeneRotex 96 Nucleic Acid Extractor, Libex Nucleic Acid Extractor, Gentier 96E/96R Real-Time PCR System, and Gentier Mini Series Portable Real-Time PCR System. These instruments exhibit outstanding performance in pathogene nucleic acid detection, guaranteeing the ability to quickly obtain precise, stable, and reliable outcomes, which enhances detection efficiency significantly. Multiple throughput can also meet various detection quantity requirements. Alongside instruments, Tianlong's compatible nucleic acid extraction and PCR detection kits have also played a crucial part in detecting livestock diseases in many countries. In Southeast Asia, Tianlong partnered with top agribusiness and food groups to undertake livestock disease detection. The process involved the use of Tianlong's Animal Virus DNA and RNA Extraction Kit, and African Swine Fever Virus (ASFV) Nucleic Acid Detection Kit (Fluorescence PCR Method). Both kits demonstrate exceptional performance in a wider range of sample types and higher sensitivity. When used in conjunction with Tianlong's instruments, it has capacity to detect large sample volume hence increase the detection rate of low concentration samples. In China, Tianlong's avian influenza detection products have been utilized effectively by Centers for Disease Control and Prevention (CDCs), animal epidemic control agencies, and medical institutions during numerous avian influenza epidemics. Furthermore, Tianlong's Avian Influenza Virus H7N9 Nucleic Acid Detection Kit (Fluorescence PCR Method), which includes the detection of both LPAI and HPAI, has gained attention in an animal disease testing laboratory in the Philippines due to its exceptional performance. To ensure adherence to strict quality standards, Tianlong has implemented a comprehensive quality management system. With ISO 13485 and ISO 9001 certifications, alongside standardized GMP product line for animal drugs, the company's focus on standardized workflows ensures the production of top-quality products. At present, Tianlong's products have been extensively used in more than 100 countries and regions globally, providing robust assistance in the prevention and control of livestock husbandry epidemics. In the future, Tianlong will continuously strive to engage in research and development to contribute its scientific and technological expertise. About Tianlong Tianlong is an innovative high-tech company specializing in molecular diagnostic products in China. Since its foundation in 1997, Tianlong has devoted itself to providing integrated PCR lab solutions for professionals worldwide. We have a wide range of products covering from devices to reagents, including nucleic acid extractors, Real-time PCR systems, All-in-one molecular diagnosis systems, sample processing systems, liquid handling systems, and 300 kinds of compatible reagents. With NMPA, CE, and FDA listing, our products have been exported to more than 100 countries and regions worldwide and have greatly helped the prevention and control of epidemics such as COVID-19, SARS, Avian influenza, Ebola, Zika, and African swine fever. For more information, please visit Tianlong's official website and its LinkedIn, Facebook, and Twitter pages. For product or corporate information inquiries may be directed to [email protected]. Media Contact: Kaylee Zhang [email protected] +86-15991940095 SOURCE Xi'an TianLong Science and Technology Co., Ltd

Anitoa's turn-key swine flu test delivers breakthrough workflow simplicity and consistent, accurate results at the point-of-care SUNNYVALE, Calif., Dec. 4, 2023 /PRNewswire/ -- Anitoa Systems, LLC, a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing, announced today worldwide availability of its all-in-one swine flu test solution for live stocks. Included in the test kit is an Anitoa's Maverick portable qPCR instrument, lyophilized swine flu test qPCR reagent, and a one-time-use sample collection tube with pre-filled lysis buffer solution. The complete turn-key test kit delivers breakthrough workflow simplicity and consistent, accurate results at the point-of-care for medium and small size farms with limited access to centralized lab tests. Anitoa's All-in-one swine flu test kit is expected to be available for sampling Q4'2023 and the company expects to ship the product in volume in 2024. Continue Reading Anitoa Systems, LLC Founded in 2013, with focus on point of care, on-site molecular tests on human, livestock and environment samples, Anitoa Systems made its first product debut by providing portable qPCR instruments to farms in Asia, mainly China, for testing farm animals. The All-in-one Swine Flu Test is part of an comprehensive menu of livestock and pet test kits offered by Anitoa. Other animal molecular tests offered by Anitoa include foot-and-mouth disease, tuberculosis, vesicular stomatitis and peste-des-petits-ruminants virus. The test kits combine sample collection, purification, and amplification detection in one package, which includes the instrument, reagent, and plastic consumables. The whole solution can easily fit into a backpack or medium suitcase. The product qualifies as a true a "lab-in-a-backpack" solution. Included in the all-in-one swine flu test kit is a 16-well Anitoa Maverick qPCR instrument with integrated Android touchpad interface. The instrument weighs less than 5 lb. and comes with a laptop style power adapter. A special adapter to draw power from car batteries or similar rechargeable batteries is also available from Anitoa systems. "Anitoa Systems was founded with deep commitment to support human, animal and environment tests with our portable, easy to use molecular testing solutions," said Dr. Zhimin Ding, CEO of Anitoa Systems, "as we believe human, animal and environmental health are connected." About Anitoa Anitoa Systems, a medical device technology start-up established in 2013 with headquarter in Sunnyvale, California, developed highly integrated and low-power CMOS-based bio-sensor devices for fluorescence and chemiluminescence sensing in portable molecular testing instruments. By replacing the traditional bulky and costly photon-multiplier tubes (PMT) and cooled CCDs, Anitoa's ultra-low-light CMOS sensor technology enables a new generation of compact and affordable molecular testing platforms targeting infectious pathogens in human, animals, our food and the environment. Anitoa manufactures its qPCR instruments and reagents in Hangzhou, China and Fremont, California, USA. For complete list of Anitoa's qPCR instrument and molecular test products please visit , or contact Anitoa Sales & PR at 408-887-6026. Media Contact: Sandra Liu 408-887-6026 [email protected] SOURCE Anitoa Systems, LLC